Klinische Studie NCT02194738 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Klinische Studie NCT02194738 ist «aktiv (nicht rekrutierend)» auf ClinicalTrials.gov.
Erkrankung: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · Registrierte Interventionen: Carboplatin, Cisplatin, Crizotinib, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium · Erfasste Daten (Quelle): 2014-09-26, 2026-09-28, 2014-07-18, 2026-08-28.
Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.